SCHEDULE: Anixa Biosciences: Catelani Boosts Stake to 7.0%

Michael Catelani increased his beneficial ownership in Anixa Biosciences, Inc. to 7.0% through market purchases and stock option exercises, including a new grant.

Summary

• Michael Catelani, a reporting person, now beneficially owns 2,468,103 shares of Anixa Biosciences, Inc. common stock.
• This represents 7.0% of the Issuer's outstanding common stock, an increase from the previously reported 5.25%.
• The ownership consists of 44,500 shares held directly and 2,423,603 shares issuable upon exercise of stock options exercisable within 60 days.
• The change in ownership is attributed to market purchases, the vesting of previously outstanding stock options, and a change in the number of stock options exercisable within 60 days.
• A triggering event for this filing was the granting of a stock option to Mr. Catelani on January 5, 2026, to purchase up to 175,000 shares of common stock at $3.18 per share.

Sentiment

Score: 7

Explanation: The increase in beneficial ownership by a key individual, including a new option grant, generally indicates confidence in the company's future prospects, which is a positive signal for investors.

Positives

• Increased beneficial ownership by Michael Catelani from 5.25% to 7.0% signals increased insider confidence in Anixa Biosciences, Inc.
• The granting of a new stock option for 175,000 shares at $3.18 per share to Mr. Catelani aligns his interests with shareholders.

Future Outlook

The filing indicates that 2,423,603 shares from stock options are exercisable within 60 days, suggesting potential future share acquisitions by the reporting person.

Industry Context

This filing primarily concerns an individual's ownership stake and does not provide information directly related to broader industry trends or competitive landscape. However, increased insider ownership can be viewed positively within the biotechnology sector as a sign of confidence.

Related Party Transactions

• The granting of a stock option to Michael Catelani, an insider, to purchase 175,000 shares at $3.18 per share on January 5, 2026, represents a transaction between the company and a related party.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management's confidence in the company's future, potentially leading to increased investor interest.
• The new stock option grant aligns the interests of Michael Catelani with those of other shareholders.

Next Steps

• Michael Catelani may exercise the 2,423,603 stock options that are exercisable within 60 days, potentially increasing his direct shareholdings.

Key Dates

Recommendation

The increase in beneficial ownership by a key individual, including a new stock option grant, is a positive signal of insider confidence. However, a Schedule 13D filing primarily reports ownership changes and does not provide comprehensive financial or operational details necessary for a 'buy' or 'sell' recommendation. Investors should 'hold' and conduct further due diligence on Anixa Biosciences' fundamentals, pipeline, and market position before making a definitive investment decision.

Keywords

Anixa Biosciences, Michael Catelani, Beneficial Ownership, Stock Options, Insider Ownership, ANIX, Schedule 13D